Related Experiment Video
Updated: May 7, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions
Linnéa Schmidt1, Teresia Kling, Naser Monsefi
1Corresponding Author: Sven Nelander, PhD, Immunology, Genetics and Pathology (IGP), Uppsala University; and Science for Life Laboratory, SE-751 85 Uppsala, Sweden.. sven.nelander@igp.uu.se.
Background:
Glioblastoma multiforme (GBM) is the most aggressive brain tumor in adults, and despite state-of-the-art treatment, survival remains poor and novel therapeutics are sorely needed. The aim of the present study was to identify new synergistic drug pairs for GBM. In addition, we aimed to explore differences in drug-drug interactions across multiple GBM-derived cell cultures and predict such differences by use of transcriptional biomarkers.
Methods:
We performed a screen in which we quantified drug-drug interactions for 465 drug pairs in each of the 5 GBM cell lines U87MG, U343MG, U373MG, A172, and T98G. Selected interactions were further tested using isobole-based analysis and validated in 5 glioma-initiating cell cultures. Furthermore, drug interactions were predicted using microarray-based transcriptional profiling in combination with statistical modeling.
Results:
Of the 5 × 465 drug pairs, we could define a subset of drug pairs with strong interaction in both standard cell lines and glioma-initiating cell cultures. In particular, a subset of pairs involving the pharmaceutical compounds rimcazole, sertraline, pterostilbene, and gefitinib showed a strong interaction in a majority of the cell cultures tested. Statistical modeling of microarray and interaction data using sparse canonical correlation analysis revealed several predictive biomarkers, which we propose could be of importance in regulating drug pair responses.
Conclusion:
We identify novel candidate drug pairs for GBM and suggest possibilities to prospectively use transcriptional biomarkers to predict drug interactions in individual cases.
Insights
Researchers identified novel synergistic drug pairs for glioblastoma multiforme (GBM), a deadly brain cancer. Transcriptional biomarkers were also found to predict drug interactions, offering personalized treatment potential.
Area of Science:
- Oncology
- Pharmacology
- Genomics
Background:
- Glioblastoma multiforme (GBM) is an aggressive adult brain tumor with poor patient survival rates.
- Current treatments for GBM are insufficient, highlighting the urgent need for novel therapeutic strategies.
- Understanding drug-drug interactions is crucial for developing effective GBM treatments.
Purpose of the Study:
- To identify novel synergistic drug combinations for glioblastoma multiforme (GBM).
- To investigate variations in drug-drug interactions across different GBM cell lines.
- To predict drug interaction variability using transcriptional biomarkers.
Main Methods:
- A large-scale screen of 465 drug pairs was conducted across five GBM cell lines (U87MG, U343MG, U373MG, A172, T98G).
- Selected drug interactions were validated using isobole-based analysis and tested in glioma-initiating cell cultures.
- Microarray-based transcriptional profiling and statistical modeling were employed to predict drug interactions.
Main Results:
- A subset of drug pairs demonstrated significant synergistic interactions in both standard and glioma-initiating cell cultures.
- Drug pairs including rimcazole, sertraline, pterostilbene, and gefitinib showed strong interactions across most tested cell cultures.
- Sparse canonical correlation analysis identified predictive biomarkers for drug pair response variability.
Conclusions:
- Novel synergistic drug pairs for GBM treatment were identified.
- Transcriptional biomarkers show promise for predicting individual drug interaction responses in GBM patients.
- This research paves the way for personalized therapeutic strategies in GBM.
